卡博替尼诱发的严重心脏功能障碍：一例报告及文献系统综述
Cabozantinib-Induced Severe Cardiac Dysfunction: A Case Report and a Systematic Review of the Literature.
作者信息
Buttar Chandan, Lakhdar Sofia, Nassar Mahmoud, Landry Ian, Munira Most
机构信息
Internal Medicine, Icahn School of Medicine at Mount Sinai, New York City Health and Hospitals/Queens, Jamaica, USA.
Internal Medicine, Queens Hospital Center, New York, USA.
出版信息
Cureus. 2022 Apr 1;14(4):e23740. doi: 10.7759/cureus.23740. eCollection 2022 Apr.
Abstract
Cabozantinib is a novel multitargeted receptor tyrosine kinase inhibitor commonly used to treat advanced renal cell carcinoma. Cardiotoxicity is not a previously well-described adverse effect of cabozantinib. We present a rare case of a 74-year-old male with a history of renal cell carcinoma who underwent partial nephrectomy. The patient had been recently started on cabozantinib for advanced metastatic renal cell carcinoma. He developed acute onset of heart failure and subclinical hypothyroidism within nine months of treatment. Our case report postulates a causal relationship between cabozantinib and the development of non-ischemic cardiomyopathy.
摘要
卡博替尼是一种新型的多靶点受体酪氨酸激酶抑制剂，常用于治疗晚期肾细胞癌。心脏毒性并非卡博替尼之前被充分描述的不良反应。我们报告一例罕见病例，一名74岁男性，有肾细胞癌病史，接受了部分肾切除术。该患者最近开始使用卡博替尼治疗晚期转移性肾细胞癌。在治疗的九个月内，他出现了急性心力衰竭和亚临床甲状腺功能减退。我们的病例报告推测卡博替尼与非缺血性心肌病的发生之间存在因果关系。
相似文献
1
Cabozantinib-Induced Severe Cardiac Dysfunction: A Case Report and a Systematic Review of the Literature.
Cureus. 2022 Apr 1;14(4):e23740. doi: 10.7759/cureus.23740. eCollection 2022 Apr.
2
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
J Med Case Rep. 2018 Nov 25;12(1):351. doi: 10.1186/s13256-018-1875-9.
3
Acute heart failure following the initiation of cabozantinib, a multikinase inhibitor: A case report.
J Cardiol Cases. 2022 Jul 5;26(3):217-220. doi: 10.1016/j.jccase.2022.04.012. eCollection 2022 Sep.
4
Reversible Cabozantinib-Induced Cardiomyopathy.
Can J Cardiol. 2019 Apr;35(4):544.e1-544.e2. doi: 10.1016/j.cjca.2018.12.025. Epub 2018 Dec 29.
5
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.
6
Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report.
J Med Case Rep. 2020 Nov 20;14(1):225. doi: 10.1186/s13256-020-02560-0.
7
Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
In Vivo. 2021 May-Jun;35(3):1743-1747. doi: 10.21873/invivo.12433.
8
Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib.
Ann Otol Rhinol Laryngol. 2020 Jul;129(7):657-661. doi: 10.1177/0003489420902161. Epub 2020 Feb 10.
9
Cabozantinib-induced heart failure.
J Oncol Pharm Pract. 2024 Jan;30(1):225-227. doi: 10.1177/10781552231203703. Epub 2023 Oct 11.
10
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Eur J Cancer. 2018 Nov;104:188-194. doi: 10.1016/j.ejca.2018.08.014. Epub 2018 Oct 28.
引用本文的文献
1
Bilateral Venous Access for Cardiac Resynchronization Therapy in a Hemodialysis Patient With Cabozantinib-associated Heart Failure.
In Vivo. 2025 May-Jun;39(3):1719-1723. doi: 10.21873/invivo.13973.
2
A fatal case of cabozantinib-induced cardiomyopathy.
Future Cardiol. 2024;20(10):537-541. doi: 10.1080/14796678.2024.2383500. Epub 2024 Aug 5.
3
Local Liver Irradiation Concurrently Versus Sequentially with Cabozantinib on the Pharmacokinetics and Biodistribution in Rats.
Int J Mol Sci. 2023 Mar 19;24(6):5849. doi: 10.3390/ijms24065849.
本文引用的文献
1
Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
In Vivo. 2021 May-Jun;35(3):1743-1747. doi: 10.21873/invivo.12433.
2
Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report.
Front Oncol. 2021 Feb 1;10:622134. doi: 10.3389/fonc.2020.622134. eCollection 2020.
3
Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports.
Front Oncol. 2020 Dec 22;10:609235. doi: 10.3389/fonc.2020.609235. eCollection 2020.
4
A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial.
Oncotarget. 2020 Nov 24;11(47):4457-4462. doi: 10.18632/oncotarget.27807.
5
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).
Oncologist. 2021 Mar;26(3):e508-e511. doi: 10.1002/onco.13617. Epub 2020 Dec 14.
6
Atypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report.
Case Rep Oncol. 2020 Aug 21;13(2):1013-1019. doi: 10.1159/000509640. eCollection 2020 May-Aug.
7
Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report.
Anticancer Res. 2020 Mar;40(3):1527-1534. doi: 10.21873/anticanres.14098.
8
Response to cabozantinib in renal cell carcinoma with cardiac metastases.
Anticancer Drugs. 2020 Mar;31(3):314-318. doi: 10.1097/CAD.0000000000000889.
9
Reversible Cabozantinib-Induced Cardiomyopathy.
Can J Cardiol. 2019 Apr;35(4):544.e1-544.e2. doi: 10.1016/j.cjca.2018.12.025. Epub 2018 Dec 29.
10
Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
Br J Clin Pharmacol. 2019 Jun;85(6):1283-1289. doi: 10.1111/bcp.13895. Epub 2019 Mar 31.
Zotero 插件